ICECURE MEDICAL RSS Feed | Nachrichten - www.finanzen.net

Icecure Medical präsentierte Quartalsergebnisse

Thu, 19 Mar 2026 06:35:06 +0100

Icecure Medical hat am 17.03.2026 die Bilanz für das jüngste Quartal veröffentlicht, das zum 31.12.2025 abgelaufen war.Das EPS wurde auf einen Verlust von 0,06 USD je Aktie beziffert. Im Vorjahresviertel waren ...

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

Wed, 17 Dec 2025 14:30:00 +0100

ProSense® systems are being sold and installed at new locations across North America, including some of the most highly regarded medical institutions in the ...

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

Wed, 10 Dec 2025 14:30:00 +0100

Abstracts presented include 3 studies involving 263 patients, adding to a growing body of evidence across diverse patient populations supporting broader adoption of ProSense®

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

Fri, 05 Dec 2025 14:30:00 +0100

Cryogenic flow control enhances the efficacy and precision of cryoablation procedures
Robust IP portfolio becomes increasingly strategic ...

Icecure Medical gab Ergebnis zum abgelaufenen Quartal bekannt

Fri, 21 Nov 2025 06:35:08 +0100

Icecure Medical äußerte sich am 19.11.2025 zu den Geschäftsergebnissen des am 30.09.2025 abgelaufenen Quartals.Für das jüngste Jahresviertel wies das Unternehmen ein EPS von -0,06 USD je Aktie aus. Ein Jahr ...

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

Wed, 19 Nov 2025 14:54:00 +0100

Momentum building in the U.S. and rising interest globally following landmark FDA marketing
authorization for local cryoablation treatment of low-risk breast cancer

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

Tue, 18 Nov 2025 14:30:00 +0100

This latest approval further broadens global access to ProSense® and supports IceCure's commercial momentum following the U.S. Food and Drug Administration's ("FDA") recent marketing authorization ...

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Fri, 14 Nov 2025 22:30:00 +0100

CAESAREA, Israel, Nov. 14, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (the "Company"), developer ...

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

Wed, 12 Nov 2025 14:30:00 +0100

CAESAREA, Israel, Nov. 12, 2025 /PRNewswire/ --

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

Mon, 10 Nov 2025 14:30:00 +0100

Mr. Levav's appointment ensures seamless and focused organizational structure as Company expands commercial activities in the U.S. following FDA marketing clearance for ProSense®